Journal of Cancer Research and Therapeutics Close
 

Figure 8: Cell cycle analysis of DU145 cells treated with (a, e) cultured medium (control), (b) 0.05 μM doxorubicin alone, (c, f) 0.95 μg/ml zinc oxide nanofluid alone, (d, g) combination of 0.05 μM doxorubicin and 0.95 μg/ml zinc oxide nanofluid. a, b, c and d in the absence of ultraviolet A; e, f and g in the presence of ultraviolet A by flow cytometry analysis

Figure 8: Cell cycle analysis of DU145 cells treated with (a, e) cultured medium (control), (b) 0.05 μM doxorubicin alone, (c, f) 0.95 μg/ml zinc oxide nanofluid alone, (d, g) combination of 0.05 μM doxorubicin and 0.95 μg/ml zinc oxide nanofluid. a, b, c and d in the absence of ultraviolet A; e, f and g in the presence of ultraviolet A by flow cytometry analysis